WeVote
Log In

Bill

Bill

HCR 72

HEALTH SERVICES: Memorialize the United States Congress to research treatment methods for Acute Myeloid Leukemia

2026 Regular Session Introduced by Roy Adams and 82 co-sponsors

Louisiana asks federal leaders to accelerate AML research, clinical trials, and treatment development, honoring Jonas A. Feeley as the act’s namesake, and sends the request to key

Taken by the Clerk of the House and presented to the Secretary of State in accordance with the Rules of the House.
0
WeVote Research Nonpartisan
Bill Summary · HCR 72

Summary of Bill: HCR 72 (2026 Regular Session, Louisiana)

Title

HEALTH SERVICES: Memorialize the United States Congress to research treatment methods for Acute Myeloid Leukemia

Purpose and Intent

  • The bill is a concurrent resolution that requests the United States Congress to expedite and prioritize research, clinical trials, and treatment development related to Acute Myeloid Leukemia (AML).
  • It designates such federal research and development efforts as the “Jonas A. Feeley Act” in honor of Jonas A. Feeley, who was diagnosed with AML in December 2025 and passed away the same month.

Key Provisions

  • The Louisiana Legislature memorializes:
    • The U.S. Congress
    • The National Institutes of Health (NIH)
    • The National Cancer Institute (NCI)
    • The U.S. Department of Health and Human Services (HHS) to accelerate and prioritize:
    • Research on AML
    • Clinical trials related to AML
    • Development of AML treatments
  • The accelerated federal efforts are to be designated as the “Jonas A. Feeley Act.”
  • The Resolution requests that copies be transmitted to:
    • The presiding officers of the U.S. Senate and House
    • Louisiana’s congressional delegation
    • The Secretary of HHS
    • The Directors of NIH and NCI

Who/What is Affected

  • Directly affects federal policy momentum by urging Congress and federal health agencies to prioritize AML research and treatment development.
  • Indirectly signals Louisiana’s support for enhanced federal action in AML research to legislators, researchers, clinicians, patients, and families.

Background and Context Provided

  • AML is described as a rare, aggressive blood cancer with rapid progression and high mortality.
  • The bill notes a 5-year survival rate around 30%, underscoring the need for better therapies and faster clinical trials.
  • It highlights the urgency given AML’s rapid progression and limited treatment windows.
  • Jonas A. Feeley’s case is cited to illustrate the disease’s speed and impact on families, providing a personal context for the designation “Jonas A. Feeley Act.”
  • Mention of environmental/occupational exposures as potential risk factors for hematologic malignancies, including AML.

Procedural and Timeline Aspects

  • Status: Read by title and lies over under the rules (as of the provided action history on 2026-04-20).
  • As a concurrent resolution, it functions to express the will or position of both chambers of the Louisiana Legislature rather than to enact statutory law.
  • There is no immediate fiscal impact or implementation requirement for state agencies; the measure is a formal request to federal action.
  • No specific dates for action by Congress are included; the resolution serves as a formal appeal/invitation for prioritization.

Summary in One Line

HCR 72 is a Louisiana House Concurrent Resolution urging the federal government to accelerate and prioritize research, clinical trials, and treatment development for Acute Myeloid Leukemia, honoring Jonas A. Feeley as the namesake for the initiative, and requesting formal transmission to federal health leadership.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.